Hepatic peroxisome proliferation: Induction by BR 931, a hypolipidemic analog of WY 14,643

J. K. Reddy, D. L. Azarnoff, C. R. Sirtori

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Administration of BR 931, an ethanolamine derivative of Wy 14,643 [4-chloro-6-(2,3 xylidino)-2-pyrimidinylthio]acetic acid, at a dietary concentration of 0.125% for 3 wk to male F 344 rats, resulted in a significant enlargement of the liver. The hepatomegaly appeared to be due to liver cell hyperplasia and hypertrophy resulting, in part, from peroxisome and smooth endoplasmic reticulum proliferation. The hepatic catalase and carnitine acetyltransferase activities increased significantly in association with peroxisome proliferation. The hepatomegaly and peroxisome proliferation induced by BR 931 were comparable in degree to those resulting from feeding of an equivalent dose of Wy 14,643. All these hepatic effects were reversible when the drugs were withdrawn from the diet. Screening of new compounds for hepatic peroxisome proliferation and for increases in peroxisome associated enzymes may prove to be an adjunct to evaluating their potency as hypolipidemic agents, in view of frequent association between hepatic peroxisome proliferation and hypolipidemia.

Original languageEnglish (US)
Pages (from-to)4-14
Number of pages11
JournalArchives internationales de pharmacodynamie et de therapie
Issue number1
StatePublished - 1978

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Hepatic peroxisome proliferation: Induction by BR 931, a hypolipidemic analog of WY 14,643'. Together they form a unique fingerprint.

Cite this